Sugi Predict

Sugi Predict / Compounds / SCHEMBL221799

SCHEMBL221799

SCHEMBL221799

CNC1CCN(C(C)C)CC1

nearest known ligand 0.42

Predicted protein targets (top 14)

geneUniProtsupporting neighboursconfidence
▸ KDM1A O60341 1/20 0.42
▸ ALDH1A1 P00352 1/20 0.41
▸ HRH3 Q9Y5N1 8/20 0.38
▸ CYP2D6 P10635 3/20 0.38
▸ WHR1 P49842 1/20 0.36
▸ NSD2 O96028 1/20 0.34
▸ MAPT P10636 1/20 0.34
▸ ACKR3 P25106 2/20 0.33
▸ HRH4 Q9H3N8 1/20 0.33
▸ KCNH2 Q12809 1/20 0.32
▸ CHRNA7 P36544 1/20 0.32
▸ CYP3A4 P08684 1/20 0.32
▸ HTR4 Q13639 1/20 0.32
▸ EHMT2 Q96KQ7 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrochloric Acid SCHEMBL2104255 0.98 KDM1A (0.41) KDM1AALDH1A1HRH3CYP2D6WHR1
SCHEMBL19623362 0.91 KDM1A (0.38) KDM1AALDH1A1HRH3CYP2D6WHR1
SCHEMBL29346783 0.91 KDM1A (0.38) KDM1AALDH1A1HRH3CYP2D6WHR1
SCHEMBL19243860 0.91 KDM1A (0.38) KDM1AALDH1A1HRH3CYP2D6WHR1
SCHEMBL24467174 0.86 KAT2B (0.36) KDM1AALDH1A1HRH3CYP2D6KCNH2
SCHEMBL2738327 0.86 HRH3 (0.39) KDM1AALDH1A1HRH3HRH4
SCHEMBL13995044 0.86 HRH3 (0.39) KDM1AALDH1A1HRH3HRH4
SCHEMBL2737372 0.86 HRH3 (0.39) KDM1AALDH1A1HRH3HRH4
SCHEMBL22456334 0.82 KDM1A (0.51) KDM1AALDH1A1HRH3CYP2D6WHR1
SCHEMBL21123407 0.82 KDM1A (0.33) KDM1AALDH1A1HRH3CYP2D6KCNH2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 217 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1490367-B1 IMIDAZOPYRIDINE DERIVATIVES AS KINASE INHIBITORS GLAXO GROUP LTD (GB) 2008-07-23 — — EP claimed
US-7348339-B2 2-(4-amino-furazan-3-yl)-1-ethyl-N-[(2R)-2-morpholinylmethyl]-1H-imidazo[4,5-c]pyridine-7-carboxamide; Mitogen- and Stress-Activated Protein (MSK) and Rho (guanosine triphosphate) 1 or 2 kinase inhibitor; neurodegenerative diaeases; antiinflammatory, anticarcinogenic, antiviral and antibacterial agent GLAXO GROUP LIMITED (GB) 2008-03-25 — — US claimed
WO-2007069053-A1 BENZIMIDAZOLE ANTAGONISTS OF THE H-3 RECEPTOR PFIZER PRODUCTS INC. (US) 2007-06-21 — — WO claimed
US-20050197328-A1 Imidazopyridine derivatives as kinase inhibitors GLAXO GROUP LIMITED (GB) 2005-09-08 — — US claimed
EP-1490367-A1 IMIDAZOPYRIDINE DERIVATIVES AS KINASE INHIBITORS GLAXO GROUP LIMITED (GB) 2004-12-29 — — EP claimed
WO-2003080610-A1 IMIDAZOPYRIDINE DERIVATIVES AS KINASE INHIBITORS GLAXO GROUP LIMITED (GB) 2003-10-02 — — WO claimed
US-20250353841-A1 HETEROCYCLIC COMPOUNDS FOR TREATING HUNTINGTON'S DISEASE HUFF SARAH ELIZABETH (US) 2025-11-20 — — US disclosed
WO-2024141757-A1 LSD1 MODULATORS EXSCIENTIA AI LIMITED (GB) 2024-07-04 — — WO disclosed
US-20240216357-A1 POLYCYCLIC COMPOUND AND APPLICATION THEREOF SICHUAN HUIYU PHARMACEUTICAL CO., LTD. (CN) 2024-07-04 — — US disclosed
EP-4393919-A1 LSD1 MODULATORS Exscientia Al Limited (GB) 2024-07-03 — — EP disclosed
WO-2024137548-A2 INHIBITORS OF JAK2 Llydaw Therapeutics, Inc. (US) 2024-06-27 — — WO disclosed
US-11911403-B2 Antisense-induced exon exclusion in type VII collagen SAREPTA THERAPEUTICS, INC. (US) 2024-02-27 — — US disclosed
US-11911403-B2 Antisense-induced exon exclusion in type VII collagen SAREPTA THERAPEUTICS, INC. (US) 2024-02-27 — — US disclosed
EP-1140905-B1 HETEROAROMATIC AMIDES AS INHIBITOR OF FACTOR XA LILLY CO ELI (US) 2003-05-14 — — EP disclosed
WO-2003024929-A1 SUBSTITUTED PIPERIDINES WITH SELECTIVE BINDING TO HISTAMINE H3-RECEPTOR NOVO NORDISK A/S (DK) 2003-03-27 — — WO disclosed
WO-2002048099-A1 CARBOXYLIC ACID AMIDE DERIVATIVES AND THEIR USE IN THE TREATMENT OF THROMBOEMBOLIC DISEASES AND TUMOURS MERCK PATENT GMBH (DE) 2002-06-20 — — WO disclosed
EP-1140905-A1 HETEROAROMATIC AMIDES AS INHIBITOR OF FACTOR XA ELI LILLY AND COMPANY (US) 2001-10-10 — — EP disclosed
EP-1140881-A1 ANTITHROMBOTIC AMIDES ELI LILLY AND COMPANY (US) 2001-10-10 — — EP disclosed
WO-2000039111-A1 ANTITHROMBOTIC AMIDES ELI LILLY AND COMPANY (US) 2000-07-06 — — WO disclosed
WO-2000039117-A1 HETEROROAROMATIC AMIDES AS INHIBITOR OF FACTOR Xa ELI LILLY AND COMPANY (US) 2000-07-06 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250353841-A1 HETEROCYCLIC COMPOUNDS FOR TREATING HUNTINGTON'S DISEASE HTT, HYPK, ATXN2 KDM1A 1980/4885ALDH1A1 2917/4885HRH3 1142/4885
US-20050197328-A1 Imidazopyridine derivatives as kinase inhibitors NR4A3, XDH, MAPK8 KDM1A 2372/4885ALDH1A1 4524/4885HRH3 1168/4885
US-11911403-B2 Antisense-induced exon exclusion in type VII collagen COL2A1, COL14A1, COL1A1 KDM1A 4175/4885ALDH1A1 4425/4885HRH3 4497/4885
US-20240216357-A1 POLYCYCLIC COMPOUND AND APPLICATION THEREOF KDM1A, TET1, KDM3A KDM1A 1/4885ALDH1A1 460/4885HRH3 1048/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.